Is the cardiovascular toxicity of NSAIDS and COX-2 selective inhibitors underestimated in patients with haemophilia?
详细信息 查看全文
- 作者：Ana Bobana ; b ; bobanana@gmail.com" class="auth_mail" title="E-mail the corresponding author ; ana.boban@zg-kbc.hr" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Catherine Lamberta ; catherine.lambert@clin.ucl.ac.be" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae ; Cedric Hermansa ; Cedric.Hermans@uclouvain.be" class="auth_mail" title="E-mail the corresponding authorAuthor Vitae
- 关键词：Cardiovascular disease ; Coxibs ; Haemophilia A ; Haemophilia B ; NSAID
- 刊名：Critical Reviews in Oncology and Hematology
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：100
- 期：Complete
- 页码：25-31
- 全文大小：798 K
文摘
- •
Patients with haemophilia often require analgesics due to haemophilic arthropathy.
- •
Advantage of coxibs over ns-NSAIDs is the reduced risk of GI bleedings.
- •
FVIII or FXI deficiency does not protect from atherosclerosis nor atherothrombosis.
- •
Coxibs may increase the cardiovascular risk in patients with haemophilia.
- •
Coxibs should be used with caution in patients with haemophilia.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |